{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:12:20Z","timestamp":1785420740852,"version":"3.56.0"},"reference-count":171,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202983"],"award-info":[{"award-number":["82202983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L252079"],"award-info":[{"award-number":["L252079"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The abscopal effect, defined as the regression of non-irradiated tumors following localized radiotherapy (RT), represents one of the most intriguing manifestations of systemic antitumor immunity. Although traditionally considered a rare and unpredictable phenomenon, increasing evidence indicates that the abscopal effect is an immune-mediated process initiated by RT-induced immunogenic cell death. In addition to directly eliminating tumor cells, RT promotes the release of tumor-associated antigens and danger-associated molecular patterns, activates antigen-presenting cells, and primes tumor-specific T-cell responses, thereby triggering systemic immune surveillance. The development of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has substantially enhanced the likelihood of inducing abscopal responses by sustaining antitumor immunity and overcoming tumor-induced immune suppression. As a result, the abscopal effect has evolved from an anecdotal clinical observation into a promising strategy for systemic cancer treatment. However, its clinical application remains limited by tumor heterogeneity, the immunosuppressive tumor microenvironment, uncertainties regarding optimal radiation dose, fractionation, and treatment sequencing, as well as the lack of reliable predictive biomarkers. In this review, we summarize the current understanding of the biological mechanisms underlying the abscopal effect, discuss its reciprocal interaction with immunotherapy, and evaluate recent advances in radio-immunotherapy. We also highlight the major challenges that impede clinical translation and discuss future strategies for biomarker development, treatment optimization, and precision radio-immunotherapy. Overall, this review provides a comprehensive overview of the current landscape of the abscopal effect and offers perspectives on its development as a predictable and clinically applicable therapeutic strategy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1871187","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:28:07Z","timestamp":1785418087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing the abscopal effect: mechanistic insights and therapeutic strategies for systemic cancer immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Linxi","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Force","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-6871","article-title":"Advances in radiotherapy and implications for the next century: a historical perspective","volume":"69","author":"Connell","year":"2009","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011061","article-title":"The abscopal effect: a review of pre-clinical and clinical advances","volume":"22","author":"Janopaul-Naylor","year":"2021","journal-title":"IJMS"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation\u2014radiobiology or medicine","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership","volume":"63","author":"Demaria","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251387534","article-title":"Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy","volume":"17","author":"Chen","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1517147","article-title":"Physical parameters and biological factors affect the abscopal effect of combining radiotherapy with immunotherapy: an update on preclinical works","volume":"12","author":"Ren","year":"2025","journal-title":"Front Public Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-48-574-863","article-title":"An interesting case of possible abscopal effect in Malignant melanoma","volume":"48","author":"Kingsley","year":"1975","journal-title":"Br J Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-46-543-220","article-title":"Abscopal effect of radiation in papillary adenocarcinoma","volume":"46","author":"Ehlers","year":"1973","journal-title":"Br J Radiol"},{"key":"B14","article-title":"Therapeutic efficacy of pre-operative radiotherapy on breast carcinoma: in special reference to its abscopal effect on metastatic lymph-nodes","volume":"25","author":"Konoeda","year":"1990","journal-title":"Nihon Gan Chiryo Gakkai Shi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1148\/93.2.410","article-title":"The abscopal effect in Malignant lymphoma and its relationship to lymphocyte circulation","volume":"93","author":"Nobler","year":"1969","journal-title":"Radiology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(77)90020-7","article-title":"Lymphangiographic demonstration of the abscopal effect in patients with Malignant lymphomas","volume":"2","author":"Antoniades","year":"1977","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005248","article-title":"Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination","volume":"10","author":"van der Woude","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-018-0349-7","article-title":"Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: report of two cases","volume":"8","author":"Matsushita","year":"2019","journal-title":"Int Cancer Conf J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1056\/nejmc1900407","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"380","author":"Antonia","year":"2019","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200042","article-title":"The abscopal effect 67 years later: from a side story to center stage","volume":"93","author":"Demaria","year":"2020","journal-title":"Br J Radiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"Jnci-Journal Natl Cancer Institute"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554499","article-title":"Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193033","article-title":"Immunogenic cell death: an emerging target in gastrointestinal cancers","volume":"11","author":"Chiaravalli","year":"2022","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.05.013","article-title":"Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein","volume":"29","author":"Kazama","year":"2008","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.497","article-title":"A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death","volume":"31","author":"Garg","year":"2012","journal-title":"EMBO J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19750","article-title":"The emergence of phox-ER stress induced immunogenic apoptosis","volume":"1","author":"Garg","year":"2012","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-025-00685-0","article-title":"Inhibition of PRC1 elicits immunogenic cell death by triggering ROS-dependent ER stress in colorectal cancer via the Wnt\/\u03b2-catenin signaling pathway","volume":"20","author":"Wang","year":"2025","journal-title":"Biol Direct"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308890","article-title":"Activation of the cGAS-STING-IRF3 axis by type I and II interferons contributes to host defense","volume":"11","author":"Tong","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2022.05.027","article-title":"cGAS\u2013STING signaling","volume":"32","author":"Sun","year":"2022","journal-title":"Curr Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","article-title":"Structures and mechanisms in the cGAS-STING innate immunity pathway","volume":"53","author":"Zhang","year":"2020","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000488952","article-title":"The cGAS\/STING pathway is important for dendritic cell activation but is not essential to induce protective immunity against Mycobacterium tuberculosis infection","volume":"10","author":"Marinho","year":"2018","journal-title":"J Innate Immun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2019.06.001","article-title":"Type I interferons and dendritic cells in cancer immunotherapy","volume":"348","author":"Sprooten","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12576","article-title":"Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors","volume":"44","author":"Wu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104745","article-title":"TGF-\u03b2 in radiotherapy: mechanisms of tumor resistance and normal tissues injury","volume":"155","author":"Farhood","year":"2020","journal-title":"Pharmacol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005474","article-title":"New tricks for an old fox: impact of TGF\u03b2 on the DNA damage response and genomic stability","volume":"7","author":"Barcellos-Hoff","year":"2014","journal-title":"Sci Signaling"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00070","article-title":"Control of the immune response by pro-angiogenic factors","volume":"4","author":"Voron","year":"2014","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.5ru0222-082r","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J Leukocyte Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-014-1206-6","article-title":"TGF-\u03b21 mediates the radiation response of prostate cancer","volume":"93","author":"Wu","year":"2015","journal-title":"J Mol Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29945","article-title":"Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human","volume":"138","author":"Andzinski","year":"2016","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00629","article-title":"The essential role of type I interferons in differentiation and activation of tumor-associated neutrophils","volume":"7","author":"Pylaeva","year":"2016","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \"N1\" versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0111","article-title":"Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer","volume":"8","author":"Yang","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response","volume":"49","author":"Marcus","year":"2018","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2104","article-title":"Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide","volume":"71","author":"Barsoum","year":"2011","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101927","article-title":"The role of the complement system in the response to cytotoxic therapy","volume":"77","author":"Lee","year":"2025","journal-title":"Semin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.03.009","article-title":"Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response","volume":"42","author":"Surace","year":"2015","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06060-z","article-title":"Cancer-associated fibroblasts: tumor defenders in radiation therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.024","article-title":"PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/srep46714","article-title":"Ionizing radiation abrogates the pro-tumorigenic capacity of cancer-associated fibroblasts co-implanted in xenografts","volume":"7","author":"Grinde","year":"2017","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662594","article-title":"Ionizing radiation curtails immunosuppressive effects from cancer-associated fibroblasts on dendritic cells","volume":"12","author":"Berzaghi","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108779","article-title":"Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination","volume":"34","author":"Yasuda","year":"2021","journal-title":"Cell Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073490","article-title":"The role of CXCL16 in the pathogenesis of cancer and other diseases","volume":"22","author":"Korbecki","year":"2021","journal-title":"IJMS"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00357-7","article-title":"IFN-\u03b3 surmounts PD-L1\/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells","volume":"6","author":"Dong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.07.015","article-title":"CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment","volume":"184","author":"Di Pilato","year":"2021","journal-title":"Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117487","article-title":"ICAM-1 and VCAM-1: gatekeepers in various inflammatory and cardiovascular disorders","volume":"548","author":"Singh","year":"2023","journal-title":"Clin Chim Acta"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0028-4","article-title":"Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity","volume":"1","author":"Carozza","year":"2020","journal-title":"Nat Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0581","article-title":"Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs","volume":"6","author":"Diamond","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1150705","article-title":"cGAMP the travelling messenger","volume":"14","author":"Blest","year":"2023","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00628-3","article-title":"Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.08.008","article-title":"Simultaneous targeting of TGF-\u03b2\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion","volume":"39","author":"Lan","year":"2021","journal-title":"Cancer Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.04.014","article-title":"Combined radiotherapy and anti\u2013PD-L1 antibody synergistically enhances antitumor effect in non\u2013small cell lung cancer","volume":"12","author":"Gong","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217935","article-title":"Radiotherapy in combination with PD-1 and TIGIT blockade mediate antitumor abscopal effects and immune memory via CD8+ T cells","volume":"631","author":"Wang","year":"2025","journal-title":"Cancer Lett"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.08.009","article-title":"Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes","volume":"36","author":"Callahan","year":"2019","journal-title":"Cancer Cell"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12348","article-title":"Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844142","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","article-title":"Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy","volume":"41","author":"Liu","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5825401","article-title":"Cancer vaccines: toward the next breakthrough in cancer immunotherapy","volume":"2020","author":"Igarashi","year":"2020","journal-title":"J Immunol Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"key":"B98","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-04923-4","article-title":"Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo","volume":"80","author":"van Eck van der Sluijs","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2021.212","article-title":"Combining oncolytic virus and radiation therapy for cancer management","volume":"8","author":"Jayalie","year":"2022","journal-title":"jcmt"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006780","article-title":"Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer","volume":"11","author":"Jhawar","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207505","article-title":"Clinical application of oncolytic viruses: a systematic review","volume":"21","author":"Cook","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B104","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA: A Cancer J For Clin"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.01.006","article-title":"Lighting up the tumor fire with low-dose irradiation","volume":"43","author":"Herrera","year":"2022","journal-title":"Trends Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00656-9","article-title":"Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation","volume":"26","author":"Morris","year":"2025","journal-title":"Lancet Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000492","article-title":"Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-22-0516","article-title":"Predicting the abscopal effect: associated tumor histologic subtypes and biomarkers","volume":"22","author":"Nelson","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1172\/jci166333","article-title":"Phenotype screens of murine pancreatic cancer identify a Tgf-\u03b1-Ccl2-paxillin axis driving human-like neural invasion","volume":"133","author":"Wang","year":"2024","journal-title":"J Clin Invest"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29620","article-title":"A review of the abscopal effect in the era of immunotherapy","volume":"14","author":"Nabrinsky","year":"2022","journal-title":"Cureus"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.01.032","article-title":"Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1\/2 trials","volume":"108","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11157-w","article-title":"Tumor-infiltrating lymphocytes (TILs) as a biomarker of abscopal effect of cryoablation in breast cancer: a pilot study","volume":"29","author":"Khan","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13082","article-title":"Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor","volume":"15","author":"\u00d6jlert","year":"2021","journal-title":"Mol Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.03.041","article-title":"Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma","volume":"104","author":"Sundahl","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2010333118","article-title":"ICAM-1 orchestrates the abscopal effect of tumor radiotherapy","volume":"118","author":"Zhao","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.723609","article-title":"The combination of radiotherapy with immunotherapy and potential predictive biomarkers for treatment of non-small cell lung cancer patients","volume":"12","author":"Meng","year":"2021","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.08.003","article-title":"Toxicity of radiation and immunotherapy combinations","volume":"3","author":"Verma","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0610","article-title":"Mathematical modeling predicts optimal immune checkpoint inhibitor and radiotherapy combinations and timing of administration","volume":"13","author":"Sakai","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"viii488","DOI":"10.1093\/annonc\/mdy291","article-title":"Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC","volume":"29","author":"Faivre-Finn","year":"2018","journal-title":"Ann Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.1479","article-title":"The combination timing of radio-immunotherapy determines immune microenvironment remodeling and abscopal effect through eosinophils","volume":"114","author":"Zhu","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00612","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation","volume":"8","author":"Buchwald","year":"2018","journal-title":"Front Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113377","article-title":"The optimal radiation dose to induce robust systemic anti-tumor immunity","volume":"19","author":"Poleszczuk","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2019.06.004","article-title":"A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer","volume":"18","author":"Floudas","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti\u2013CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01018-w","article-title":"Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Nat Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.002","article-title":"Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer","volume":"108","author":"Yin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1423","article-title":"Abscopal benefits of localized radiotherapy depend on activated T-cell trafficking and distribution between metastatic lesions","volume":"76","author":"Poleszczuk","year":"2016","journal-title":"Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0942-3","article-title":"Radiation-induced bystander and abscopal effects: important lessons from preclinical models","volume":"123","author":"Daguenet","year":"2020","journal-title":"Br J Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2034","article-title":"Radiotherapy and immunotherapy for cancer: from \u2018systemic\u2019 to \u2018multisite\u2019","volume":"26","author":"Arina","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2013.07.023","article-title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors","volume":"82","author":"Griffioen","year":"2013","journal-title":"Lung Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318262caf6","article-title":"Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)","volume":"7","author":"De Ruysscher","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01058-2","article-title":"Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial","volume":"7","author":"Gu","year":"2026","journal-title":"Nat Cancer"},{"key":"B151","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00262-024-03934-9","article-title":"Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-\u03b11 in advanced metastatic solid tumors: a multicenter phase II clinical trial","volume":"74","author":"Yu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2010057","article-title":"Phase 1\/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma","volume":"63","author":"Halwani","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B153","doi-asserted-by":"publisher","first-page":"22397","DOI":"10.1038\/s41598-022-27048-3","article-title":"Phase Ib\/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer","volume":"12","author":"Takada","year":"2022","journal-title":"Sci Rep"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109679","article-title":"Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: an open-label, single-arm, phase II trial","volume":"184","author":"Zhao","year":"2023","journal-title":"Radiother Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100752","article-title":"Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed\/refractory cancers","volume":"6","author":"Lin","year":"2025","journal-title":"Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.502","article-title":"Phase II trial of combined durvalumab plus tremelimumab with proton therapy for recurrent or metastatic head and neck squamous cell carcinoma","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B157","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1038\/s41467-024-51807-7","article-title":"Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: the multicenter SWORD phase 2 trial","volume":"15","author":"Ni","year":"2024","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/iju5.12203","article-title":"Editorial comment from Dr Kojima to possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma","volume":"3","author":"Kojima","year":"2020","journal-title":"IJU Case Rep"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104690","article-title":"Irradiation combined with PD-L1-\/- and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation","volume":"25","author":"Zhao","year":"2022","journal-title":"iScience"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2025-000732","article-title":"Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trials","volume":"4","author":"Urias","year":"2025","journal-title":"BMJ Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1200\/JCO.2025.43.16_suppl.8110","article-title":"Combining SBRT with GM-CSF and peg-IFN\u03b1 to induce abscopal effects in previously treated patients with stage IV thymic tumors: a single arm, single center, phase II trial","volume":"43","author":"Fan","year":"2025","journal-title":"J Clin Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4632","article-title":"A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer","volume":"27","author":"Monjazeb","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.690188","article-title":"Abscopal effects of local radiotherapy are dependent on tumor immunogenicity","volume":"11","author":"Lai","year":"2021","journal-title":"Front Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1871187\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:28:10Z","timestamp":1785418090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1871187\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":171,"alternative-id":["10.3389\/fimmu.2026.1871187"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1871187","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1871187"}}